VIEMED HEALTHCARE, INC.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Non-GAAP Financial Measures
The Company uses Adjusted EBITDA, which is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management believes Adjusted EBITDA provides helpful information with respect to the Company’s operating performance as viewed by management, including a view of the Company’s business that is not dependent on the impact of the Company’s capitalization structure and items that are not part of the Company’s day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company’s operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company’s employees, (iii) for planning purposes, including the preparation of the Company’s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company’s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company’s operating performance in the same manner as management. It is not a measurement of our financial performance under GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with GAAP or as an alternative to cash flows from operating activities as a measure of the Company's liquidity. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our operating results as reported under GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters we consider not to be indicative of ongoing operations; and other companies in our industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure. In calculating Adjusted EBITDA, certain items (mostly non-cash) are excluded from net income attributable to Viemed Healthcare, Inc. including depreciation and amortization of capitalized assets, net interest expense, stock based compensation, transaction costs, impairment of assets, and taxes.
The following table is a reconciliation of net income attributable to Viemed Healthcare, Inc., the most directly comparable GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:
| For the quarter ended | September 30, 2025 | June 30, 2025 | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Net income attributable to Viemed Healthcare, Inc. | $3,513 | $3,157 | $2,625 | $4,316 | $3,878 | $1,468 | $1,603 | $3,477 |
| Add back: | ||||||||
| Depreciation & amortization | 7,539 | 6,891 | 6,613 | 6,366 | 6,408 | 6,309 | 6,285 | 5,918 |
| Interest expense, net | 507 | 132 | 179 | 147 | 225 | 254 | 150 | 256 |
| Stock-based compensation(a) | 2,180 | 2,341 | 2,311 | 1,521 | 1,712 | 1,620 | 1,432 | 1,534 |
| Transaction costs(b) | 847 | 53 | 85 | 11 | 12 | 221 | 110 | 61 |
| Impairment of assets(c) | — | — | — | — | 125 | 2,173 | — | — |
| Income tax expense | 1,535 | 1,713 | 952 | 1,881 | 1,594 | 768 | 518 | 1,599 |
| Adjusted EBITDA | $16,121 | $14,287 | $12,765 | $14,242 | $13,954 | $12,813 | $10,098 | $12,845 |
(a) Represents non-cash, equity-based compensation expense associated with option and RSU awards.
(b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions.
(c) Represents impairments of the fair value of investment and litigation-related assets.
Page 36
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.